Intersect ENT (XEXT) Stock Gains After Upsizing Secondary Offering

NEW YORK (TheStreet) -- Intersect ENT  (XENT) shares are climbing 2.5% to $25.79 in trading on Wednesday after the commercial stage drug device company upsized its secondary offering by 582,000 shares to 3.582 million shares.

The company priced its offering at $25 per share, a slight decrease from yesterday's closing price of $25.16, resulting in aggregate proceeds of $89.6 million.

J.P. Morgan (JPM) and Bank of America/Merrill Lynch (BAC) are acting as joint book-running managers for the offering.

XENT Chart XENT data by YCharts

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists